World Health Organization and Essential Medicines

J Pharm Sci. 2018 May;107(5):1261-1262. doi: 10.1016/j.xphs.2017.12.019. Epub 2017 Dec 24.

Abstract

In June 2017, the World Health Organization released 20th Model List of Essential Medicines for adults and sixth Model List of Essential Medicines for children. In our commentary, we describe the changes to the Essential Medicine list, and identify deficits in excluding medicines for management of diseases with a high burden. In using tracer conditions such as cardiovascular and thromboembolic disease, mental health, and diseases of the musculoskeletal system, we highlight the absence of several medicines, which are incorporated into major clinical practice guidelines. We recommend that the World Health Organization review its process with respect to identifying disease conditions as well as evidence-based therapies.

Keywords: HIV/AIDS; clinical trials; global health; targeted drug delivery; vaccine delivery.

MeSH terms

  • Adult
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / economics
  • Cardiovascular Diseases / epidemiology
  • Child
  • Communicable Diseases / drug therapy
  • Communicable Diseases / economics
  • Communicable Diseases / epidemiology
  • Drugs, Essential / economics
  • Drugs, Essential / supply & distribution*
  • Global Health* / economics
  • Humans
  • Mental Disorders / drug therapy
  • Mental Disorders / economics
  • Mental Disorders / epidemiology
  • Musculoskeletal Diseases / drug therapy
  • Musculoskeletal Diseases / economics
  • Musculoskeletal Diseases / epidemiology
  • Thromboembolism / drug therapy
  • Thromboembolism / economics
  • Thromboembolism / epidemiology
  • World Health Organization

Substances

  • Drugs, Essential